Neuropsychiatric Disease and Treatment
Open access peer-reviewed scientific and medical journals.
Dove Medical Press is now a member of the Open Access Initiative
An Author's Guide
A guide to help authors get their paper published.
Support Open Access and Dove Press
Promotional Article Monitoring - further details
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review
(11325) Total Article Views
Authors: Paul Hammerness, Katherine McCarthy, Elizabeth Mancuso, Cassandra Gendron, Daniel Geller
Published Date March 2009
Volume 2009:5 Pages 215 - 226
Paul Hammerness, Katherine McCarthy, Elizabeth Mancuso, Cassandra Gendron, Daniel Geller
Clinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital and Harvard Medical School, Cambridge, MA, USA
Objective: This review examines and summarizes the pharmacodynamic and pharmacokinetic properties, short- and longer-term efficacy, the moderating effect of comorbid disorders, as well as short- and long-term safety and tolerability of atomoxetine for the treatment of pediatric attention-deficit/hyperactivity disorder (ADHD).
Methods: A systematic literature search was performed to review the extant literature on articles pertaining to the pharmacological treatment with atomoxetine in pediatric and/or adolescent ADHD.
Results: There is an extensive literature on atomoxetine; over 4000 children have participated in clinical trials of atomoxetine, demonstrating its short- and longer-term efficacy. In addition, studies have examined the moderating effect of comorbid disorders on atomoxetine response, as well as atomoxetine’s therapeutic potential for other psychiatric conditions. Short- and longer-term safety and tolerability continue to be reported.
Conclusions: Atomoxetine is indicated for both acute and maintenance/extended treatment of pediatric ADHD. Clinicians and families must be familiar with atomoxetine’s evidence base, including its profile of clinical response and its possible effectiveness in the presence of comorbidity.
Keywords: ADHD, atomoxetine, pediatric
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Readers of this article also read:
"I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University.
- MLA'14 -
May 16–21, 2014
- CINP World Congress
22 - 26 June, 2014
- 27th ECNP Congress
18 - 21 October, 2014
- Neuroscience 2014 Annual Meeting
November 15 - 19
- Aggressive behavior, cognitive impairment, and depressive symptoms in elderly subjects
- Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy
- Role of nucleus accumbens glutamatergic plasticity in drug addiction
- Long-term treatment of bipolar disorder with a radioelectric asymmetric conveyor